To determine the propensity of the CEA antibodies in the sera of Ad5 [E1-, E2b-]-CEA or Tri-Ad5 vaccinated mice to lyse tumor cells expressing CEA, we utilized a complement-dependent cytotoxicity (CDC) assay. Here, CEACAM5 is linked to neoplasm.